VENCLEXTA Fact Sheet
Venclexta® (also known as Venetoclax) is a prescribed oral tablet approved by the Food and Drug Administration for adult patients with acute myeloid leukemia (AML)
Acute Myeloid Leukemia (AML)
Order Patient Educational Materials
AAMDSIF provides educational materials for patients and healthcare professionals written in plain language and reviewed by highly respected and recognized medical doctors who are experts in bone marrow failure
Outpatient Low-Dose Venetoclax-Azacitidine vs. Intensive Therapy in Newly Diagnosed AML in Resource-Limited Settings
Original Publication Date
Article Source
External Web Content
Key points Outpatient low-dose VenAza plus itraconazole reduced early mortality and hospitalizations while maintaining treatment efficacy. VenAza offers a safer, cost-effective alternative to intensive chemotherapy in newly diagnosed AML. Abstract Acute myeloid leukemia (AML)…
Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia
Original Publication Date
Article Source
External Web Content
Highlights Heme biosynthesis enzymes are variably suppressed in AML Heme levels are linked with altered leukemic transcriptional programs via BACH1 Heme biosynthesis is a selective dependency in AML, both in vitro and in vivo Heme starvation disrupts complex IV, inducing copper…
Transplant Patient Card
Emergency health information card for patients who have received a transplant.
Non Transplant Patient Card
Emergency health information card for patients who have not received a transplant.
Instructions
Not all healthcare professionals or emergency responders will understand your rare diagnosis and unique needs. AAMDSIF has created an emergency health information card that communicates to others what they need to know…
10th International Bone Marrow Failure Disease Scientific Symposium
Topic(s)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
The 10th International Bone Marrow Failure Disease Scientific Symposium will convene physicians, laboratory researchers and clinical investigators to discuss current areas of consensus and controversy, share recent research results, and clarify promising directions for…
ASH 2021 MDS and AML - for Patients
This publication offers summaries of selected abstracts presented at the December 2021 Meeting of the American Hematology Society. It provides new and updated information about new research into the diagnosis, treatment…
ASH 2022 MDS and AML - Booklet
This publication offers summaries of selected abstracts presented at the Annual Meeting of the American Hematology Society held in December 2022. It provides new and updated information about research into the diagnosis…